This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) advanced 1.55% to $97.08 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&amp;P 500 Index rising 1.08% to 7,432.97 and the Dow Jones Industrial Average rising 1.31% to 50,009.35.
This was the stock's second consecutive day of gains.
Incyte Corp. closed 13.55% below its 52-week high of $112.29, which the company reached on January 7th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 1.42% to $298.48, Bio-Techne Corp. (TECH) rose 2.71% to $46.70, and BioMarin Pharmaceutical Inc. (BMRN) rose 0.78% to $50.20.
Trading volume (1.1 M) remained 431,006 below its 50-day average volume of 1.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled May 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-20-26 1707ET

INCY

Incyte Corp. (INCY) shares rose 1.55% to $97.08 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.08%, while the Dow Jones Industrial Average rose 1.31%. Incyte's stock remains 13.55% below its 52-week high of $112.29. Trading volume was 1.1 million, below the 50-day average of 1.5 million.

MarketWatch Automated

Incyte

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares US Pharma

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

S&P 500

Dow Jones Industrial Average

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day